Hypogonadism screening: Difference between revisions
Jump to navigation
Jump to search
| (4 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
According to the endocrine society, screening for hypogonadism is recommended. Hypogonadism screening | According to the endocrine society, screening for hypogonadism is not recommended as it is not cost-effective. Hypogonadism screening may be done in order to diagnose the disease early and provide the appropriate treatment. Screening may be done for men who present with [[erectile dysfunction]], [[infertility]], [[HIV]], and young patients with [[Osteoporosis (patient information)|osteoporosis]]. | ||
==Screening== | ==Screening== | ||
Screening for hypogonadism is not recommended by the endocrine society as it | Screening for hypogonadism is not recommended by the endocrine society as it is not cost-effective. However, it may be performed in men who are thought to be at high risk of having hypogonadism. Screening is performed in men showing the following:<ref name="pmid27132573">{{cite journal| author=Ross A, Bhasin S| title=Hypogonadism: Its Prevalence and Diagnosis. | journal=Urol Clin North Am | year= 2016 | volume= 43 | issue= 2 | pages= 163-76 | pmid=27132573 | doi=10.1016/j.ucl.2016.01.002 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27132573 }} </ref><ref name="pmid20525905">{{cite journal| author=Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS et al.| title=Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. | journal=J Clin Endocrinol Metab | year= 2010 | volume= 95 | issue= 6 | pages= 2536-59 | pmid=20525905 | doi=10.1210/jc.2009-2354 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20525905 }}</ref> | ||
*[[Erectile dysfunction]] | *[[Erectile dysfunction]] | ||
*[[Infertility]] | *[[Infertility]] | ||
*[[HIV]] infected individuals | *[[HIV]] infected individuals | ||
* | *Patients with previous exposure to [[radiation]] on the [[brain]] | ||
*Young patients with [[osteoporosis]]. | *Young patients with [[osteoporosis]]. | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Latest revision as of 20:43, 3 October 2017
|
Hypogonadism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hypogonadism screening On the Web |
|
American Roentgen Ray Society Images of Hypogonadism screening |
|
Risk calculators and risk factors for Hypogonadism screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]
Overview
According to the endocrine society, screening for hypogonadism is not recommended as it is not cost-effective. Hypogonadism screening may be done in order to diagnose the disease early and provide the appropriate treatment. Screening may be done for men who present with erectile dysfunction, infertility, HIV, and young patients with osteoporosis.
Screening
Screening for hypogonadism is not recommended by the endocrine society as it is not cost-effective. However, it may be performed in men who are thought to be at high risk of having hypogonadism. Screening is performed in men showing the following:[1][2]
- Erectile dysfunction
- Infertility
- HIV infected individuals
- Patients with previous exposure to radiation on the brain
- Young patients with osteoporosis.
References
- ↑ Ross A, Bhasin S (2016). "Hypogonadism: Its Prevalence and Diagnosis". Urol Clin North Am. 43 (2): 163–76. doi:10.1016/j.ucl.2016.01.002. PMID 27132573.
- ↑ Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS; et al. (2010). "Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline". J Clin Endocrinol Metab. 95 (6): 2536–59. doi:10.1210/jc.2009-2354. PMID 20525905.